Protocolsmental health
mental healthModerate-High

Psychedelic-Assisted Therapy (Psilocybin, MDMA)

Guided therapeutic sessions using psychedelic compounds (psilocybin, MDMA, ayahuasca) to catalyze psychological breakthroughs and healing.

Evidence Score

83/100

Developer

Various (MAPS, Johns Hopkins, Imperial College)

Duration

1-3 dosing sessions over 2-6 months with integration therapy

Steps

9 phases

Conditions

5 targeted

Protocol Overview

Guided therapeutic sessions using psychedelic compounds (psilocybin, MDMA, ayahuasca) to catalyze psychological breakthroughs and healing. Preparation, dosing session, and integration therapy. Emerging FDA-approved treatments.

Conditions Treated

Treatment-resistant depressionPTSDend-of-life anxietyaddictionOCD

Key Resources

MAPS.org (MDMA for PTSD), Johns Hopkins psychedelic research, Imperial College, "How to Change Your Mind" by Michael Pollan

Safety Profile

Contraindications & Risks
Psychosis risk (screen for schizophrenia), cardiovascular issues (MDMA), interacts with SSRIs, must be done with trained guides, illegal in most jurisdictions (changing)
Important Notes

Revolutionary results: MDMA 67% PTSD remission vs 33% placebo in Phase 3 trials. Psilocybin shows rapid antidepressant effects. FDA approved MDMA-assisted therapy 2024. Legal only in clinical trials or specific jurisdictions. Underground therapy exists. Set and setting critical. Not recreational use.

Find a Practitioner

Connect with practitioners experienced in this protocol.

Browse Practitioners
EvidenceModerate-High
Evidence Score83/100
Categorymental health
Duration1-3 dosing sessions over 2-6 months with integration therapy

About Evidence Score

The Evidence Score rates the strength of clinical and scientific evidence behind this protocol. Higher scores indicate stronger research support. This is a research tool, not medical advice.

Educational purposes only. Some alternative protocols carry serious risks. Always consult qualified healthcare professionals before beginning any treatment.